Reproxalap for Dry Eye Syndrome

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Aldeyra Therapeutics, Inc.

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap

Eligibility Criteria

This trial is for individuals with Dry Eye Disease, a condition where eyes do not stay properly lubricated. Participants should have a confirmed diagnosis and may need to meet other specific health criteria set by the study.

Inclusion Criteria

I am 18 years old or older.

Exclusion Criteria

I do not have an eye infection or inflammation right now.

Treatment Details

The trial is testing the effectiveness of Reproxalap ophthalmic solution (0.25%) compared to a vehicle (placebo) solution in improving symptoms of dry eye. It's conducted at multiple centers, with participants randomly assigned to either treatment.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Reproxalap Ophthalmic Solution (0.25%)Experimental Treatment1 Intervention

Group II: Vehicle Ophthalmic SolutionPlacebo Group1 Intervention